Lantheus Holdings, Inc.
Every calculator, already run for LNTH
Open the full toolkit →You have the numbers on LNTH. Get the argument.
A written report on which of these readings actually decide the outcome for Lantheus Holdings, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
10 analysts covering LNTHAnalyst Price Target Disagreement for Lantheus Holdings, Inc.
Wall Street's bull case implies +15% from the current price; the bear case implies +3%. Analysts are relatively aligned on LNTH's range.
Ownership & short interest
Insider Trading Activity for LNTH
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18…
LNTH — frequently asked
Is LNTH a buy right now?
Wall Street's consensus rating on Lantheus Holdings, Inc. is none across 10 analysts, with a mean price target of $107.74 (+8% vs. the current $99.74). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is LNTH overvalued?
LNTH trades at 23.9x trailing earnings, against a DCF fair value of $269 per share. The current price implies -6% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is LNTH's next earnings date?
Lantheus Holdings, Inc. is next scheduled to report earnings around Nov 5, 2026. A full LNTH research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Lantheus Holdings, Inc.?
Analysts covering Lantheus Holdings, Inc. (LNTH) range from a bear-case target of $102.50 to a bull-case high of $115.00, with a mean consensus target of $107.74 across 8 analysts. The spread of $12.50 (13% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Lantheus Holdings, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Lantheus Holdings, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full LNTH research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Lantheus Holdings, Inc., in minutes. 3 free reports included with every account — no credit card required.